balofloxacin (Q 35)

showed potent bactericidal activity & inhibited the supercoiling activity of DNA gyrase of S. aureus, E. coli, & P aeruginosa; structure given in first source

Also Known As:

Q 35; 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methylaminopiperidine-1-yl)-4-oxoquinoline-3-carboxylic acid; Q-35; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-(methylamino)-1-piperidinyl)-4-oxo-

Networked: 16 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - Quinolones: 2938
        Fluoroquinolones: 5348
        balofloxacin: 16

Experts

1.	Anagoni, Suresh Pal: 1 article (09/2018)
2.	Borkar, Roshan M: 1 article (09/2018)
3.	Shankar, G: 1 article (09/2018)
4.	Srinivas, R: 1 article (09/2018)
5.	Udutha, Suresh: 1 article (09/2018)
6.	Guo, Chuanlong: 1 article (08/2014)
7.	Han, Shasha: 1 article (08/2014)
8.	Jiang, Haoran: 1 article (08/2014)
9.	Liu, Ting: 1 article (08/2014)
10.	Wu, Xianggen: 1 article (08/2014)

Related Diseases

1.	Respiratory Tract Infections (Respiratory Tract Infection) 02/01/2003 - "Chugai and Ciba were developing balofloxacin for respiratory tract infections (RTI) but discontinued development in 1995 due to changes in Chugai's R&D focus and a lack of efficacy of the drug. " 03/01/1995 - "In respiratory tract infections with Streptococcus pneumoniae TMS-3 in mice, Q-35 showed a therapeutic effect similar to sparfloxacin and tosufloxacin. "
2.	Infections 09/01/1993 - "These results suggest that both Q-35 and ofloxacin are effective in the early phase of infection and, moreover, that Q-35 is also effective in the middle stage of infection, when progressive lung alterations and continuous increases in mycoplasmal growth occur. " 03/01/1995 - "Q-35 showed almost the same activity as that of ofloxacin in mice with pyelonephritic infection due to Escherichia coli TMS-3. " 09/01/1993 - "On the basis of these results, Q-35 appears to be a promising antimicrobial agent in chemotherapy of mycoplasmal infection." 09/01/1993 - "Q-35 and ofloxacin were efficacious following oral administration of 200 mg/kg/day for 5 days, initiated 24 h after infection, while ciprofloxacin was not active. "
3.	Critical Illness (Critically Ill) 01/01/2004 - "Mean values of cardiac output were similar in the low shunt group (Qs/Qt < 20), with r2=0.90 and a bias of 0.01 l/min+/-0.4; conversely, in the high pulmonary shunt group (Qs/Q > 35%) the mean was 9.32+/-1.23 l/min with thermodilution and a mean NICO2CO value was 6.97+/-1.53 l/min, with r2 of 0.38 and a bias of -2.3 l+/-1.2 min. The partial CO2 rebreathing technique is reliable in measuring cardiac output in nonpostoperative critically ill patients affected by diseases causing low levels of pulmonary shunt, but underestimates it in patients with shunt higher than 35%." 01/01/2022 - "Recent studies have demonstrated the use of POCUS for evaluation of cardiac tamponade, pneumonia, vocal cord function, and loss of muscle mass in critically ill children (Hamilton et al. Pediatr Crit Care Med 22(10):e532-e539, 2021; Hoffmann et al. Pediatr Crit Care Med 22(10):889-897, 2021; Najgrodzka et al. Ultrasound Q 35(2):157 163, 2019; Alerhand et al. Pediatr Ann 50(10):e424-e431, 2021). "
4.	Drug-Related Side Effects and Adverse Reactions 01/01/2001 - "The incidence of specific adverse events associated with individual fluoroquinolones was reviewed in a five-year post-marketing surveillance (PMS) study in Japan, in which a total adverse drug reaction (ADR) rate of 1.3% was found for levofloxacin, compared to total ADR rates of 3.3% for pazufloxacin, 3.6% for tosufloxacin, 4.5% for gatifloxacin and 5.4% for balofloxacin. "
5.	Pneumonia (Pneumonitis) 01/01/2022 - "Recent studies have demonstrated the use of POCUS for evaluation of cardiac tamponade, pneumonia, vocal cord function, and loss of muscle mass in critically ill children (Hamilton et al. Pediatr Crit Care Med 22(10):e532-e539, 2021; Hoffmann et al. Pediatr Crit Care Med 22(10):889-897, 2021; Najgrodzka et al. Ultrasound Q 35(2):157 163, 2019; Alerhand et al. Pediatr Ann 50(10):e424-e431, 2021). "

Related Drugs and Biologics

1.	Ofloxacin (Ofloxacine)
2.	Fluoroquinolones
3.	Levofloxacin (Levaquin)
4.	Gatifloxacin (Zymar)
5.	tosufloxacin
6.	pazufloxacin
7.	Anti-Bacterial Agents (Antibiotics)
8.	Therapeutic Uses
9.	Interferon-alpha (Interferon Alfa)
10.	Ophthalmic Solutions (Eye Drops)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Oral Administration